Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT04150497 is registered in ClinicalTrials.gov with Cellectis S.A. as lead sponsor.

NCT NCT04150497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04150497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
Lead sponsor
Cellectis S.A.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 14, 2019
Completion date
June 30, 2026
Enrollment
52 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia